About Us

GEUS Technology

Aniling owns the GEUS technology, which unifies genetic and epigenetic sequencing and provides end-to-end solutions for the right treatment decisions in oncology. Based on GEUS, Aniling is developing a set of products for cancer diagnostic.

GEUS-CLL

The first Aniling product is the most comprehensive Chronic Lymphocytic Leukemia Next Generation Sequencing diagnostics panel. The GEUS-CLL delivers accurate staging and treatment decisions. Aniling S.L. provides the GEUS-CLL diagnostic test as a service to other laboratories and hospitals.

Latest News

gummy sequencing by MAP

DNA Day 2023

Let’s take a moment to celebrate two remarkable milestones in science. Today marks the 70th anniversary of the discovery of the DNA double helix and the 20th anniversary of the …